Últimas noticias sobre aTyr Pharma (NASDAQ:ATYR) Bolsa

aTyr Pharma

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Inc

News

General

RDHL

RedHill Biopharma Plans To Submit FDA Approved Talicia Used To Treat H. Pylori Infection For UK Marketing Approval

Biotech

Health Care

PRME

Prime Medicine Unveiled A Preclinical Program For The Treatment Of Alpha-1 Antitrypsin Deficiency, The Next Program Within Its Liver Franchise. Prime Medicine Expects To File An Investigational New Drug And/Or Clinical Trial Application In Mid-2026

TLRY

Tilray Brands Company Manitoba Harvest Expands Into Functional Snacking With New Superseed Snack Clusters

BABA

RYDE

Ryde Assimilates Alipay To Boost Payment Experience For International Visitors In Singapore

Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.52) by 42.76 percent. This is a 24.35 percent increase over losses of $(1.15) per share from the same period last year.

Earnings

ACXP

Acurx Pharmaceuticals FY 2024 GAAP EPS $(0.87) Beats $(1.52) Estimate

Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) with a Buy and maintains $14 price target.

Price Target

Analyst Ratings

CRVO

Chardan Capital Maintains Buy on CervoMed, Maintains $14 Price Target

KRRO

Korro Bio 2020 EPS $(9.37)

Management

NeoGenomics Promotes Warren Stone To President & COO, Effective April 1, 2025

D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Buy and maintains $22 price target.

RCEL

D. Boral Capital Maintains Buy on AVITA Medical, Maintains $22 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) with a Buy and maintains $3.5 price target.

Reiteration

MDAI

HC Wainwright & Co. Reiterates Buy on Spectral AI, Maintains $3.5 Price Target

RYTM

Rhythm Pharmaceuticals To Form Research Partnership With Raymond A. Wood Foundation To Study The Impact Of Fatigue On Persons With Craniopharyngioma

enCore Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EU#NASDAQ">EU</a>) (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/EU#TSXV">EU</a>) (the "Company" or "enCore"), America's Clean Energy Company&#x2122;, announced today that it has entered into a share purchase agreement (the "Agreement") with Verdera Energy Corp. ("Verdera") pursuant to which Verdera will acquire an enCore subsidiary that holds the Crownpoint, Hosta Butte, Nose Rock, West Largo, and Ambrosia Lake – Treeline uranium projects located in New Mexico (the "Properties") in exchange for 50,000,000 non-voting preferred shares (the "Consideration Shares") of Verdera representing approximately 73% of the current issued and outstanding shares of Verdera on a fully diluted basis,; a 2% net proceeds royalty on uranium, and a 2% net smelter returns royalty on other minerals, extracted and sold from the Properties, and a non-refundable cash payment of US $350,000. The transaction with Verdera represents the fourth and largest transaction to date in enCore's ongoing program of divesting uranium assets that are not in its production pipeline.

Asset Sales

TSXV:EU

enCore Energy Enters Agreement To Sell A Subsidiary That Holds Multipe Uranium Projects In Exchange For 50,000,000 Non-Voting Preferred Shares Of Verdera, A 2% Net Proceeds Royalty On Uranium, 2% Net Smelter Returns Royalty On Other Minerals And $350K In Cash

Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) climbed 3.24% during the pre-market session on Tuesday, following an analyst upgrade
What Happened: Morgan Stanley has upgraded its rating for Lucid, recognizing the potential for the company&#8217;s new management to steer it towards artificial intelligence (AI) and <a href="https://www.benzinga.com/25/02/43588718/lucid-ceo-envisions-ev-maker-licensing-tech-more-than-building-cars">beyond</a> its current role as an electric vehicle manufacturer.
Morgan Stanley analyst Adam Jonas has shifted their rating for Lucid from Underweight to Equal-Weight. Jones believes Lucid could utilize strategic and independent partnerships to expand its electric vehicle manufacturing capacity.
Despite challenges, the company stands to gain from the U.S.&#8217;s heightened emphasis on domestic EV manufacturing, particularly given China&#8217;s dominance in the industry as per Morgan Stanley.
Lucid&#8217;s Gravity SUV is seen as a significant demonstration of the company&#8217;s 2nd generation software-defined vehicle architecture, which could enable Lucid&nbsp;to participate in AI-enabled autonomy&nbsp;through strategic partnerships. 
"We see emerging scope for Lucid's ability to play a role in the embodied AI theme&#8221; stated Jones in the note. 
SEE ALSO: <a href="https://www.benzinga.com/markets/equities/25/03/44371754/billionaire-investor-david-teppers-everything-china-bet-pays-off-with-alibaba-up-40-since-september">Billionaire Investor David Tepper&#8217;s &#8216;Everything&#8217; China Bet Pays Off With Alibaba Up 40% Since September</a>
Why It Matters: Lucid has been facing a challenging business environment, marked by sluggish EV sales and widening losses. The sudden&nbsp;exit of CEO Peter Rawlinson&nbsp;in February 2025 further impacted the company&#8217;s stock. However, analysts have noted a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43984093/lucid-stock-falls-on-q4-results-ceo-exit-analysts-see-surge-in-demand-for-gravity-suv">potential surge in demand</a> for Lucid&#8217;s Gravity SUV.
The company&#8217;s interim CEO, Marc Winterhoff, has also stated that customers are opting for <a href="https://www.benzinga.com/25/02/43966461/lucid-to-up-production-increase-advertising-and-sell-in-saudi-arabia-to-up-high-end-gravity-suv-sales-this-year">high-end configurations</a> of the Gravity SUV, with purchases exceeding $120,000. This, coupled with the company&#8217;s potential to expand into AI-enabled autonomy, could provide a much-needed boost for Lucid&#8217;s business.
Besides strategic product offering Jones also stated that Lucid, backed by Saudi Arabia's sovereign wealth fund, benefits from the country&#8217;s strategic location, infrastructure, Middle Eastern market access, and potential for reliable renewable energy, offering key strategic advantages.
Lucid holds a momentum rating of 13.96% and a growth rating of 80.25%, according to&nbsp;<a href="https://www.benzinga.com/report/LCID" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s Proprietary Edge Rankings</a>. The Benzinga Growth metric evaluates a stock's historical earnings and revenue expansion across multiple timeframes, prioritizing both long-term trends and recent performance. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
Lucid stock rose 3.35% to close at $2.16 on Monday. Over the past month, the stock plunged nearly 38%
READ MORE:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44359276/dogecoin-was-worth-50-billion-on-donald-trumps-inauguration-day-its-now-down-to-25-billion">Dogecoin Was Worth $50 Billion On Donald Trump&#8217;s Inauguration Day: It&#8217;s Now Down To $25 Billion</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

Tech

LCID

Lucid Stock Climbs Over 3% In Pre-Market: What's Going On?

Former NASA astronaut José Hernández stated on Monday that human travel to Mars is far away.
What Happened: During an interview <a href="https://thehill.com/policy/transportation/5199874-former-nasa-astronauts-mars/">with</a> The Hill, Hernández said travel to Mars is still &#8220;a good 15 years away,".
Hernández emphasized that space travel is complex and requires significant advancements, particularly in developing and testing technologies on a lunar base. He highlighted that the current technical challenges are too significant to overcome in the near term.
Hernández noted that the International Space Station will be retired, and its operational funds should be redirected to lunar base development. This approach would help address the technical hurdles that currently stand in the way of Mars exploration.
SEE ALSO:<a href="https://www.benzinga.com/general/space/25/03/44370917/nasa-astronauts-sunita-williams-and-butch-willmore-head-back-to-earth-on-spacex-dragon-capsule"> NASA Astronauts Sunita Williams And Butch Willmore Head Back To Earth On SpaceX Dragon Capsule</a>
His remarks came just before astronauts Butch Wilmore and Suni Williams were scheduled to return to Earth after a nine-month mission on the International Space Station.
On Sunday, NASA announced that it had coordinated with SpaceX, owned by tech billionaire Elon Musk, to plan for the astronauts&#8217; return to Earth, aiming for a Tuesday splashdown off Florida&#8217;s coast, contingent on favorable weather conditions.
Why It Matters: The timeline for human exploration of Mars has been a topic of debate, with differing opinions on when it might be feasible. Elon Musk, CEO of SpaceX, has been vocal about his ambitious plans to send humans to Mars. In March 2025, Musk suggested that <a href="https://www.benzinga.com/25/03/44350440/elon-musk-confirms-starship-to-carry-tesla-optimus-to-mars-by-2026-predicts-human-landing-by-2029">SpaceX&#8217;s Starship</a> could carry Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Optimus robots to Mars by 2026, with human landings potentially starting by 2029, though 2031 seems more likely.
Additionally, Musk has indicated that making Mars self-sustaining could take up to half a century, requiring multiple Earth-Mars transfer windows. He has also called for the <a href="https://www.benzinga.com/general/space/25/02/43875844/spacex-ceo-elon-musk-calls-for-deorbiting-space-station-ahead-of-timeline-in-2027-lets-go-to-mars">deorbiting of the International Space Station</a> ahead of schedule to focus efforts on Mars colonization.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link.</a>
Read Next:
<a href="https://www.benzinga.com/25/03/44354592/warren-buffett-backed-byd-eyes-germany-for-third-european-plant-amid-tariff-concerns-report">Warren Buffett-Backed BYD Eyes Germany For Third European Plant Amid Tariff Concerns: Report</a>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

SPACE

Media

TSLA

Former NASA Astronaut Predicts Mars Travel Still 15 Years Away: 'Not 5 Years As Elon Musk Alludes To'

Following the completion of the business combination, Kyivstar Group Ltd., the parent company of Kyivstar, will be listed on Nasdaq under the ticker symbol KYIV.
VEON will own a minimum of 80% of the issued and outstanding equity of Kyivstar Group immediately following the closing of the Business Combination, which is expected to occur in Q3 2025 and is subject to the approval of Cohen Circle's shareholders and other customary closing conditions.
 &nbsp;

VEON

VEON, Cohen Circle Sign Business Combination Agreement That Will Result In The Listing Of JSC Kyivstar On Nasdaq

SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) reported quarterly sales of $257.68 million which beat the analyst consensus estimate of $248.10 million by 3.86 percent. This is a 3.71 percent increase over sales of $248.45 million the same period last year.

SNDL

SNDL Q4 Sales C$257.68M Beat C$248.10M Estimate

Digital Realty Form JV Bersama Digital Infrastructure Asia To Develop And Operate Data Centers Across Indonesia

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and maintains $18 price target.

Telsey Advisory Group Maintains Market Perform on Guess, Maintains $18 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) with a Market Perform and maintains $3 price target.

LESL

Telsey Advisory Group Maintains Market Perform on Leslies, Maintains $3 Price Target

STOK

Stoke Therapeutics CEO Edward Kaye To Step Down; Director Ian Smith Appointed As Interim CEO And Arthur Tzianabos Appointed As Interim Executive Chairman

Press Releases

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update